Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q68CP9
UPID:
ARID2_HUMAN
Alternative names:
BRG1-associated factor 200; Zinc finger protein with activation potential; Zipzap/p200
Alternative UPACC:
Q68CP9; Q15KG9; Q5EB51; Q645I3; Q6ZRY5; Q7Z3I5; Q86T28; Q96SJ6; Q9HCL5
Background:
AT-rich interactive domain-containing protein 2, also known as BRG1-associated factor 200, plays a pivotal role in chromatin remodeling. This process is crucial for the transcriptional activation and repression of select genes, influencing DNA-nucleosome topology. It ensures the stability of the SWI/SNF chromatin remodeling complex SWI/SNF-B (PBAF) and may target the complex to specific genes, including those involved in cardiac function.
Therapeutic significance:
The protein's mutation is linked to Coffin-Siris syndrome 6, characterized by intellectual disability and physical malformations. Understanding the role of AT-rich interactive domain-containing protein 2 could open doors to potential therapeutic strategies for this syndrome, highlighting its significance in genetic research and drug discovery.